Since approximately 30% of NSCLC patients who undergo curative-intent surgery develop recurrence, and 50–90% of recurrences occur within the first two years after surgery [16], we next analyzed the correlation between the incidence of cancer recurrence and the changes in the level of anti-ENO1 Ab before and 1 month after surgery in patients with 2 years of follow ups. This evidence concerns the gene ENO1 and cancer.